Publications by authors named "Isabel Nicolas de Prado"
Introduction: Crohn's disease (CD) varies by location, potentially affecting therapy efficacy and surgery risk, although research on this topic is conflicting. This study aims to investigate the independent association between CD location and therapeutic patterns.
Methods: We analyzed patients with CD diagnosed from January 2005 to May 2023 registered in the nationwide ENEIDA registry.
Background: Understanding the relationship between ustekinumab (UST) exposure and clinical outcomes in inflammatory bowel disease (IBD) induction is crucial. However, evidence remains limited, highlighting the need to comprehend UST's pharmacokinetic variability for tailored treatments.
Aims: This study aimed to investigate the association between UST exposure during the induction phase and clinical outcomes and identifying factors associated with UST exposure during this period.
Background: Studies have investigated the efficacy and safety of switching to the biosimilar infliximab (CT-P13) in patients with inflammatory bowel disease (IBD). However, there is limited research directly comparing the effectiveness, drug survival, and pharmacokinetic profiles of the reference infliximab (IFX) and CT-P13 in real clinical settings.
Objective: To compare the effectiveness and drug survival of CPT-13 and reference IFX at weeks 26 and 52, and to determine the pharmacokinetic profiles and safety profile in real-world settings.
Article Synopsis
- The study explores the effectiveness of proactive therapeutic drug monitoring (TDM) using a Bayesian approach to optimize infliximab dosing in patients with inflammatory bowel disease (IBD) during the induction phase.
- A total of 153 IBD patients were analyzed, with one group receiving standard therapy adjustments and another using TDM; results showed the TDM group had significantly higher primary response rates and better outcomes.
- The findings suggest that implementing proactive TDM can lead to more effective treatment responses and fewer complications in the short term compared to standard monitoring methods.
Background And Objectives: There is increasing evidence that proactive monitoring is useful in improving the control of inflammatory bowel disease, although it remains controversial. The aim of this study was to evaluate the efficacy of proactive TDM based on the Bayesian approach to optimise the IFX dose compared with the standard of care dosing in patients with IBD.
Methods: Retrospective observational cohort of inflammatory bowel disease patients>18 years.
Background: efficacy and safety were evaluated after switching to a biosimilar infliximab (CPT-13) in patients with inflammatory bowel disease (IBD). However, few cohort studies compare the pharmacokinetic profiles, immunogenicity, and safety of the reference infliximab (IFX) and CPT-13 in a real clinical setting.
Objective: to compare the pharmacokinetic profiles and drug survival on the long term of reference IFX and CPT-13 at weeks 54 and 104.
Introduction: numerous studies have shown a positive correlation between serum biologic drug concentrations and favorable therapeutic outcomes during the induction and maintenance period in patients with Crohn's disease (CD). To our knowledge, only a few and contradictory studies have determined the association between ustekinumab (UST) trough concentrations and biological outcomes. This study aimed to investigate the relationship between ustekinumab trough concentrations and biological outcomes in a real-world setting.
View Article and Find Full Text PDFIntroduction: informed consent is necessary for invasive procedures as a document that guarantees the ethical health relationship and patient safety.
Aims: to analyze whether we have and use informed consent documents for paracentesis in our hospitals and to obtain data on the technique.
Methods: a descriptive observational study was performed during December 2019, via a cross-sectional survey disseminated through social networks, aimed at specialists and residents of gastroenterology.
Introduction: infliximab is used in inflammatory bowel disease, which has a great inter-individual pharmacokinetic variability. Thus, it is necessary to individualize the therapy in many cases. The main objective of our study was to compare two methods of a dose adjustment strategy using therapeutic drug monitoring: a) based on an algorithm and b) based on Bayesian prediction, to achieve an optimal infliximab trough level in patients with inflammatory bowel diseases.
View Article and Find Full Text PDFArticle Synopsis
- Higher infliximab trough levels are linked to better outcomes for patients with inflammatory bowel disease, prompting the need for proactive drug monitoring during the induction phase.
- In a study of 30 patients, only 43.3% reached target infliximab levels after six weeks, with those achieving higher levels showing significantly better clinical and biochemical responses by week 26.
- The findings suggest that therapeutic drug monitoring could be crucial for improving treatment effectiveness during the early stages of infliximab therapy.
Tuberculosis is a common infection worldwide. In developed countries, the incidence of this disease was low until a few years ago. However, due to the rise in immigration and HIV infection, the frequency of tuberculosis has recently shown a marked increase.
View Article and Find Full Text PDF